Women Face Burden of Medical Complications, Psychologic Distress Around Cervical Cancer Diagnosis

“This study for the first time systematically examined the risks of injuries during the cervical diagnostic workup,” said corresponding author Qing Shen, PhD.

A study published in Cancer Epidemiology, Biomarkers & Prevention revealed that women experienced burden of medical complications and psychologic distress around the time of a potential cervical cancer diagnosis.1

“Cervical cancer screening is one of the most successful cancer prevention programs which has greatly reduced cervical cancer incidence and mortality,” corresponding author Qing Shen, PhD, researcher in the Department of Medical Epidemiology and Biostatistics at the Karolinska Institutet in Stockholm, said in a press release.2 “Despite these substantial benefits, our research indicates that women with invasive cervical cancer experienced medical complications and psychological stress during their diagnostic workup.”

In this cohort study, researchers evaluated 3,016,307 Swedish women that participated in cervical screening from 2001 to 2012. Using this data, researchers calculated the incidence rates (IR) of hospitalized iatrogenic or noniatrogenic injuries experienced throughout a given patients’ diagnostic workup, as well as the time interval from smear or punch biopsy until surgical treatment or 2 months after the last smear or biopsy, among women with invasive cervical cancer (ICC) or its precursor lesions. In addition, the IRs of injuries during the 2 months following a normal smear among the other women were also calculated as a reference.

When compared with other women, researchers found there was an increased rate of iatrogenic injuries during the diagnostic workup of women with ICC (IR, 0.58 per 1,000 person-months; IRR, 8.55; 95% CI, 3.69-19.80) as well as of women with cervical intraepithelial neoplasia of grade 3 and adenocarcinoma in situ. Moreover, an increased rate of noniatrogenic injuries during the diagnostic workup of women with invasive cancer was also observed (IR, 0.65 per 1,000 person-months; IRR, 2.48; 95% CI, 1.30-4.47).

“An increase in non-iatrogenic injuries points to high levels of psychological distress in relation to receiving a diagnosis of cervical cancer,” Shen explained in the release. “Women with cervical cancer can be criticized about their sexual behaviors, leading to a social stigma that could contribute to this stress.”

“This study for the first time systematically examined the risks of injuries during the cervical diagnostic workup,” added Shen. “Although the chance of having such injuries was rare, we found an increased risk of inpatient care for iatrogenic and non-iatrogenic injuries for women with invasive cervical cancer. It is important to emphasize, however, that cervical cancer screening is greatly beneficial for the early detection of cancer and is largely safe.”

Importantly though, this study lacked information regarding nonsurgical treatments, including palliative care, chemotherapy, and radiotherapy, for women with ICC. Information on cancer stage was also not available during the entire study period.

Additionally, these study results may not be generalizable to other populations, as screening protocols may vary by population.


1. Shen Q, Lu D, Andrae B, et al. Risk of Injuries Around Diagnosis of Cervical Cancer and Its Precursor Lesions: A Nationwide Cohort Study in Sweden. Cancer Epidemiology, Biomarkers & Prevention. doi: 10.1158/1055-9965.EPI-20-0673

2. Women With Cervical Cancer May Have Increased Risk of Injury During Diagnostic Workup [news release]. Philadelphia. Published October 21, 2020. Accessed October 21, 2020.

Related Videos
Following the results of the phase 3 CALLA trial, Jyoti S. Mayadev, MD, discusses the importance of global clinical multidisciplinary efforts in the locally advanced cervical cancer space.
The randomized, placebo-controlled, double-blind phase 3 CALLA trial assessed the combination of durvalumab and chemoradiotherapy vs placebo and chemoradiotherapy.
Findings from the phase 3 CALLA trial indicated that intensity modulated radiation therapy was administered in 88.1% of patients with high-risk locally advanced cervical cancer treated with durvalumab and chemoradiotherapy vs 88.1% with placebo and chemoradiotherapy.
Jyoti S. Mayadev, MD, indicated that durvalumab (Imfinzi) plus chemotherapy resulted in low rates of high-grade late-onset toxicities in the phase 3 CALLA trial, which may be due in part to the quality of the technology employed during the study.
Jyoti S. Mayadev, MD, indicated that future research for cervical cancer will be focused on combination immune checkpoint inhibitors and biomarker research.
Durvalumab appeared to have no impact on the ability to deliver safe and timely radiation therapy to patients with high-risk locally advanced cervical cancer, according to Jyoti S. Mayadev, MD.
The 12-month progression-free survival rates among patients with high-risk locally advanced cervical cancer were comparable with durvalumab plus chemoradiotherapy vs placebo plus radiotherapy.
Cervical Cancer
woman speaking with physician
Related Content